TAG:
IVD
Astorg Makes Billion-Dollar Bet on Microbiology Testing
By Janette Wider | From the Volume XXXIII, No. 7 – May 26, 2026 Issue
Thermo Fisher Scientific has agreed to sell its microbiology business to European private equity firm Astorg in a deal valued at $1.075 billion. The transaction, announced in April, includes $1.025 billion in cash and a $50 million seller note. It is expected to …
For IVD Companies, Tariff Refunds May Be a Long Haul
By Mark Terry | From the Volume XXXIII, No. 5 – April 13, 2026 Issue
Following the US Supreme Court’s decision declaring certain tariffs illegal, the diagnostics industry has entered a murky period regarding potential refunds. For in vitro diagnostics (IVD) manufacturers who paid these tariffs under policies f…
Global IVD Woes in China Should Resonate with US Labs
By Mark Terry | From the Volume XXXIII, No. 3 – March 2, 2026 Issue
In vitro diagnostics (IVD) companies reported a mix of overall growth, with many noting continuing challenges in their diagnostics divisions for recent quarterly financial results. Thermo Fisher Scientific, QuidelOrtho, and Danaher reported the…
Top Stories in 2025 Played Out in Courts, Capitol Hill
By Janette Wider | From the Volume XXXII, No. 18 – December 29, 2025 Issue
CEO SUMMARY: The biggest story of the year for clinical laboratories came in a huge court victory, as a federal judge vacated the FDA’s final rule on laboratory developed tests. Labs breathed a sigh of relief after the court decision, as the FDA rule had promised to incr…
Abbott Bets Hard on Cancer Diagnostics with New Deal
By Scott Wallask | From the Volume XXXII, No. 17 – December 8, 2025 Issue
Abbott Laboratories’ deal to acquire Exact Sciences for $23 billion emphasizes the value that the in vitro diagnostics (IVD) manufacturer puts on cancer testing. Clinical laboratories involved with oncology should monitor the progres…
Insights on Innovative Tech and Running a Clinical Lab in 2026
By Scott Wallask | From the Volume XXXII, No. 17 – December 8, 2025 Issue
CEO SUMMARY: William Morice II, MD, PhD, the CEO at Mayo Clinic Laboratories, discusses technology that intrigues him and the important steps clinical laboratory leaders can take to better steer revenue opportunities as they head into the new year. Morice also comments on …
Reforms in China Affect IVD Companies’ Q3 2025 Earnings
By Mark Terry | From the Volume XXXII, No. 16 – November 17, 2025 Issue
Most of the in vitro diagnostics (IVD) manufacturers that serve clinical laboratories worldwide reported facing financial “headwinds” in the China IVD market that affected their third-quarter performance. This was due to policy changes in the country…
What Private Equity Sees in Diagnostics
By Scott Wallask | From the Volume XXXII, No. 16 – November 17, 2025 Issue
CEO SUMMARY: Hologic’s acquisition by private equity firms Blackstone and TPG marks one of the year’s largest in vitro diagnostics transactions and a clear vote of confidence in the sector’s resilience. Industry analyst Bruce Carlson unpacks what the buyout …
November 17, 2025, Intelligence: Late-Breaking Lab News
By Robert Michel | From the Volume XXXII, No. 16 – November 17, 2025 Issue
Dealmaking continues in the in vitro diagnostics (IVD) industry as AI-driven genomics and private equity reshape the market for a data-first future. On Nov. 4, Qiagen said it will acquire Parse Biosciences for $280 million to expand its reach into single-cell sequencing, levera…
October 27, 2025, Intelligence: Late-Breaking Lab News
By Robert Michel | From the Volume XXXII, No. 15 – October 27, 2025 Issue
In yet another shuffling of the in vitro diagnostics (IVD) space, Hologic announced on Oct. 21 that it was being acquired by private equity firms Blackstone and TPG for $18.3 billion. The deal will take Hologic off the Nasdaq, likely in early 2026. TPG and Blackstone lauded Hol…
CURRENT ISSUE
Volume XXXIII, No. 7 – May 26, 2026
Momentum is building on Capitol Hill to pass the RESULTS Act, which would stave off drastic 15% reimbursement cuts under PAMA. Advocates seek lobbying help from clinical labs and anatomic pathology practices. Also, The Dark Report examines Roche’s deal to acquire PathAI.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized